Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Sodium cromoglycate exerts anti-pulmonary fibrosis effects by targeting the Keap1 protein to activate Nrf2 signaling.
Bioorg Chem
December 2024
Department of Pharmacology, School of Life Sciences and Biopharmaceutical Science, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address:
Oxidative stress has been confirmed to be closely related to the occurrence and development of pulmonary fibrosis (PF). The Kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid-2 related factor 2 (Nrf2) pathway plays a key role in maintaining cellular redox homeostasis. Targeting the Keap1 protein to activate Nrf2 could be a promising strategy for treating PF.
View Article and Find Full Text PDFMast Cells Mediate Acute Inflammatory Responses After Glenoid Labral Tears and Can Be Inhibited With Cromolyn in a Rat Model.
Am J Sports Med
November 2024
Department of Bioengineering, University of Texas at Arlington, Arlington, Texas, USA.
Background: Injuries to the glenoid labrum have been recognized as a source of joint pain and discomfort, which may be associated with the inflammatory responses that lead to the deterioration of labral tissue. However, it is unclear whether the torn labrum prompts mast cell (MC) activation, resulting in synovial inflammatory responses that lead to labral tissue degeneration.
Purpose: To determine the potential influence of activated MC on synovial inflammatory responses and subsequent labral tissue degeneration and shoulder function deterioration in a rat model by monitoring MC behavior and sequential inflammatory responses within the synovial tissue and labral tissue after injury, suture repair, and MC stabilizer administration.
Cromolyn sodium and masitinib combination inhibits fibroblast-myofibroblast transition and exerts additive cell-protective and antioxidant effects on a bleomycin-induced in vitro fibrosis model.
Pharmacol Res Perspect
October 2024
Vocational High School of Health Services, Department of Medical Laboratory Techniques, Alanya Alaaddin Keykubat University, Alanya, Turkey.
Article Synopsis
- * A study explored combining two medications, masitinib and cromolyn sodium, to see if together they could help fight against tissue damage in the lungs caused by IPF.
- * The results showed that this combination could protect lung cells and might be a promising new treatment, potentially needing lower doses and causing fewer side effects.
Repurposing of known drugs from multiple libraries to identify novel and potential selective inhibitors of HDAC6 via approach and molecular modeling.
Heliyon
August 2024
Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Kadir Has University, 34083, Cibali, Istanbul, Turkey.
Histone deacetylase 6 (HDAC6, Class IIb) is a promising target for anticancer drugs. So far, few nonselective HDAC inhibitors have received regulatory approval as anticancer agents. However, they are associated with cell toxicity.
View Article and Find Full Text PDFPharmacological inhibition of PDGF-C/neuropilin-1 interaction: A novel strategy to reduce melanoma metastatic potential.
Biomed Pharmacother
July 2024
Laboratory of Molecular Oncology, IDI-IRCCS, Rome, Italy. Electronic address:
Article Synopsis
- Activation of neuropilin-1 (NRP-1) by PDGF-C promotes melanoma invasiveness, leading researchers to explore this interaction as a target for new treatments to reduce melanoma spread.
- By analyzing the structural similarities between PDGF-C and VEGF-A, scientists hypothesized that a specific region on NRP-1 involved in VEGF-A binding might also interact with PDGF-C.
- After screening compounds from DrugBank, two existing medications, gliclazide and entrectinib, were identified as effective in disrupting the PDGF-C/NRP-1 interaction, thereby inhibiting melanoma cell migration and invasion at non-toxic levels.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!